Robin L. Rasor, Managing Director of Licensing at the Office of Technology Transfer of the University of Michigan, is planned to speak in the thrilling session “How to partner more efficiently with charities, foundations and patient groups”.
Speaking alongside Olivier Arnaud, European Research Director at JDRF and scheduled December 2nd at 9am, this second day’s first session promises to raise heated debates !
Robin shares with us today her feelings on the session :
“The University of Michigan has funding and relationships with many foundations, however, its relationship with the Leukemia and Lymphoma Foundation (LLS) has been considerably more collaborative than more traditional contracts. In a recent partnership related to menin-MLL inhibitors with applications for treatment of leukemia and potentially other cancers, LLS provided cost sharing for some of the more expensive national stage patent filings as well as for CROs to do chemical synthesis under direction from the UM principal investigators, thereby freeing up their lab time for more inventive and creative endeavors. In late 2014, UM licensed the portfolio to Kura Oncology, a clinical stage biopharmaceutical company focused on the development of precision medicines, which in addition to other typical financial terms also agreed to continue funding in the principal investigator’s lab. Robin Rasor, Managing Director of Licensing at UM, will be prepared to discuss the pros and cons of such creative partnerships with foundations.”
Interested in speaking during BioFIT 2015 : contact us here